CEACAM6 has been reported to be an immune checkpoint modulator capable of inhibiting the antitumor activity of effector T cells.[18] The CAR‐T therapy targeting CEACAM6 potently inhibits the growth of pancreatic cancer tumor models both in vitro and in vivo.[19] Tinurilimab, an anti‐CEACAM6 monoclonal antibody has embarked on phase I clinical studies for the treatment of solid tumors.[20] Owing to the heterogeneity of the tumor or the complexity of the tumor microenvironment, the therapeutic effect of immunotherapy alone is frequently restricted. Here, CEACAM6 is linked to familial pancreatic carcinoma.